Re: What else can RVX treat that we don’t know about yet?
|
2
|
Resverlogix Corp.
|
Mar 30, 2019 10:01PM
|
Re: J&J Abiraterone going generic
|
2
|
Zenith Epigenetics
|
Nov 21, 2018 03:48PM
|
Re: Don't look now but...
|
2
|
Resverlogix Corp.
|
May 08, 2019 10:48AM
|
Re: ACC 2019 Abstracts
|
2
|
Resverlogix Corp.
|
Mar 19, 2019 12:10PM
|
Re: ACC 2019 Abstracts
|
2
|
Resverlogix Corp.
|
Mar 19, 2019 12:18PM
|
Re: ACC 2019 Abstracts
|
2
|
Resverlogix Corp.
|
Mar 19, 2019 01:25PM
|
Re: HDL Functionality
|
2
|
Resverlogix Corp.
|
May 08, 2019 05:03PM
|
Re: MOA of Apabetalone - only affects sick patients
|
2
|
Resverlogix Corp.
|
Apr 15, 2019 08:46AM
|
Re: Probability of Phase 3 trial success
|
2
|
Resverlogix Corp.
|
Jun 22, 2019 07:52PM
|
Re: BETonMACE Placebo Estimate
|
2
|
Resverlogix Corp.
|
Feb 20, 2019 06:11PM
|
Re: HDL Functionality
|
2
|
Resverlogix Corp.
|
May 08, 2019 05:27PM
|
HDL Functionality
|
2
|
Resverlogix Corp.
|
May 06, 2019 10:31AM
|
Recent Publication / Aug 14 / Libb
|
2
|
Resverlogix Corp.
|
Aug 16, 2019 08:30AM
|
Re: Resverlogix H2 2018 events
|
2
|
Resverlogix Corp.
|
Nov 05, 2018 12:40PM
|
Re: Resverlogix H2 2018 events
|
2
|
Resverlogix Corp.
|
Nov 05, 2018 01:03PM
|
Table In Publication / Aug 14 / Libby
|
2
|
Resverlogix Corp.
|
Aug 16, 2019 09:29AM
|
Re: NASH is a $35 Billion US/year market
|
2
|
Resverlogix Corp.
|
Dec 31, 2018 09:38PM
|
Re: 3 point MACE vs 5 point MACE
|
2
|
Resverlogix Corp.
|
Nov 02, 2018 06:27PM
|
Re: 3 point MACE vs 5 point MACE
|
2
|
Resverlogix Corp.
|
Nov 02, 2018 11:06PM
|
Lockup
|
2
|
Resverlogix Corp.
|
May 17, 2019 09:53AM
|